MedTrace Logo

Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)

NCT00563927 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 340

Last updated 2010-07-07

No results posted yet for this study

Summary

To test the therapeutic ratio of additional chemotheray on advanced nasopharyngeal carcinoma.

Conditions

  • Nasopharyngeal Neoplasms
  • Carcinoma, Squamous Cell

Interventions

PROCEDURE

Conventional RT

DRUG

Cisplatin

DRUG

5-fluorouracil

Sponsors & Collaborators

  • Hong Kong Nasopharyngeal Cancer Study Group Limited

    collaborator OTHER

  • Hospital Authority, Hong Kong

    lead OTHER_GOV

Principal Investigators

  • Wai Hon LAU, Dr · Department of Clinical Oncology, Queen Elizabeth Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-03-31
Completion
2009-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00563927 on ClinicalTrials.gov